Find what you're looking for by browsing or searching our online archives.
Browse by Category:
Search by keyword:
Categories: Pancreatic, Solid Tumor Malignancies
November 2006 Volume 4, Issue 11
Wells A. Messersmith, MD, Manuel Hidalgo, MD, PhD, Michael Carducci, MD, and S. Gail Eckhardt, MD
MAPK/ERK kinase (MEK) inhibitors constitute a promising class of novel targeted therapies. Although some of the initial clinical results with these compounds were disappointing, newer agents with more advantageous pharmacokinetic and pharmacodynamic properties have entered clinical trials. Partial responses have been seen in patients with advanced melanoma and pancreatic cancer, along with prolonged stable disease in several tumor types. Rash, diarrhea, edema, and visual disturbances have been common toxicities. With the recent finding that cell lines with B-raf mutations are exquisitely sensitive to these compounds, the possibility of genetic-based patient selection and indiviualized therapy has been raised. Whether these predictions will be borne out in clinical testing remains to be seen.